SGP
SpyGlass Pharma, Inc.
NASDAQ: SGP · HEALTHCARE · BIOTECHNOLOGY
$32.51
-1.07% today
Updated 2026-10-29
Market cap
$875.00M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.51
Dividend yield
—
52W range
$17 – $32
Volume
0.1M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$44.00
+35.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Altman Z -1.36 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-16.77M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-13.32M | $-29.16M | $-39.87M | $-19.86M |
| EPS | — | — | — | $-2.51 |
| Free cash flow | $-12.49M | $-24.02M | $-33.49M | $-16.77M |
| Profit margin | — | — | — | — |
Peer comparison
Smart narrative
SpyGlass Pharma, Inc. trades at $32.51. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -1.36, it sits in the distress.
Frequently asked questions
What is SpyGlass Pharma, Inc.'s stock price?
SpyGlass Pharma, Inc. (SGP) trades at $32.51.
Is SpyGlass Pharma, Inc. overvalued?
SpyGlass Pharma, Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of SpyGlass Pharma, Inc. (SGP)?
The 12-month analyst consensus target is $44.00, about 35.3% above the current $32.51. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
SpyGlass Pharma, Inc.'s Altman Z-Score is -1.36, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-24.12%
Beta—
50D MA$26.50
200D MA$24.09
Shares out0.03B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week+11.51%
1 month+18.94%
3 months+41.03%
YTD—
1 year—
3 years—
5 years—